MKI67 and cancer: Unfortunately, we were not able to identify significant differences between low and high Ki67 cancers in terms of: age at diagnosis, FIGO stage, grading or histological subtype, CA-125 level at diagnosis, type of surgery at diagnosis (upfront, IDS, and no surgery) and residual disease at first surgery, CA-125 before starting PARPi, BRCA status, first PFI, number of previous lines of chemotherapy, clinical response to platinum, number of surgeries before PARPi, and residual disease at last surgery.